Cargando…
Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083171/ https://www.ncbi.nlm.nih.gov/pubmed/37032401 http://dx.doi.org/10.1038/s41392-023-01355-1 |
| _version_ | 1785021450288103424 |
|---|---|
| author | Shao, Miner Yao, Jie Wang, Yunke Zhao, Lufeng Li, Baizhou Li, Lili Wu, Zuqun Chen, Zexin Fan, Junqiang Qiu, Fuming |
| author_facet | Shao, Miner Yao, Jie Wang, Yunke Zhao, Lufeng Li, Baizhou Li, Lili Wu, Zuqun Chen, Zexin Fan, Junqiang Qiu, Fuming |
| author_sort | Shao, Miner |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10083171 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100831712023-04-11 Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial Shao, Miner Yao, Jie Wang, Yunke Zhao, Lufeng Li, Baizhou Li, Lili Wu, Zuqun Chen, Zexin Fan, Junqiang Qiu, Fuming Signal Transduct Target Ther Letter Nature Publishing Group UK 2023-04-10 /pmc/articles/PMC10083171/ /pubmed/37032401 http://dx.doi.org/10.1038/s41392-023-01355-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Shao, Miner Yao, Jie Wang, Yunke Zhao, Lufeng Li, Baizhou Li, Lili Wu, Zuqun Chen, Zexin Fan, Junqiang Qiu, Fuming Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial |
| title | Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial |
| title_full | Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial |
| title_fullStr | Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial |
| title_full_unstemmed | Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial |
| title_short | Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial |
| title_sort | two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoscore trial |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083171/ https://www.ncbi.nlm.nih.gov/pubmed/37032401 http://dx.doi.org/10.1038/s41392-023-01355-1 |
| work_keys_str_mv | AT shaominer twovsthreecyclesofneoadjuvantsintilimabpluschemotherapyforresectablenonsmallcelllungcancerneoscoretrial AT yaojie twovsthreecyclesofneoadjuvantsintilimabpluschemotherapyforresectablenonsmallcelllungcancerneoscoretrial AT wangyunke twovsthreecyclesofneoadjuvantsintilimabpluschemotherapyforresectablenonsmallcelllungcancerneoscoretrial AT zhaolufeng twovsthreecyclesofneoadjuvantsintilimabpluschemotherapyforresectablenonsmallcelllungcancerneoscoretrial AT libaizhou twovsthreecyclesofneoadjuvantsintilimabpluschemotherapyforresectablenonsmallcelllungcancerneoscoretrial AT lilili twovsthreecyclesofneoadjuvantsintilimabpluschemotherapyforresectablenonsmallcelllungcancerneoscoretrial AT wuzuqun twovsthreecyclesofneoadjuvantsintilimabpluschemotherapyforresectablenonsmallcelllungcancerneoscoretrial AT chenzexin twovsthreecyclesofneoadjuvantsintilimabpluschemotherapyforresectablenonsmallcelllungcancerneoscoretrial AT fanjunqiang twovsthreecyclesofneoadjuvantsintilimabpluschemotherapyforresectablenonsmallcelllungcancerneoscoretrial AT qiufuming twovsthreecyclesofneoadjuvantsintilimabpluschemotherapyforresectablenonsmallcelllungcancerneoscoretrial |